Physician profile
Andrew B Wolf
NPI 1376551051
$2,047.56
in general payments reported to CMS, 2019-2025
22 companies · $403 in 2025
The $403 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $632 · 2020: $54.45 · 2022: $47.13 · 2023: $434 · 2024: $477 · 2025: $403.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,314.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,313.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Oyster Point Pharma, INC. | $209.40 | 2022-2025 | Tyrvaya |
| Sun Pharmaceutical Industries INC. | $202.84 | 2019-2025 | Cequa |
| Tarsus Pharmaceuticals, INC. | $200.43 | 2024-2025 | Xdemvy |
| Bausch & Lomb Americas INC. | $181.69 | 2022-2025 | Vyzulta, Miebo, Xiidra |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $173.85 | 2019-2020 | |
| Kala Pharmaceuticals, INC. | $173.00 | 2019-2020 | |
| Abbvie INC. | $144.48 | 2023-2024 | Durysta, Vuity |
| Alcon Vision LLC | $109.09 | 2023-2025 | Eysuvis, Rocklatan |
| Novartis Pharmaceuticals Corporation | $93.81 | 2019-2023 | |
| Aerie Pharmaceuticals, INC. | $75.13 | 2019 | |
| Dompe US, INC. | $70.40 | 2023-2025 | Oxervate |
| Rayner Intraocular Lenses Limited | $64.59 | 2024-2025 | Rayone Spheric, Rayone Aspheric, Rayone Emv |
| Thea Pharma INC. | $60.21 | 2024-2025 | Iyuzeh |
| Shire North American Group INC | $56.87 | 2019 | |
| Biotissue Holdings INC. | $52.11 | 2023-2024 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sight Sciences, INC. | $29.54 | 2020-2022 | |
| Johnson & Johnson Vision Care, INC. | $28.19 | 2019-2023 | Acuvue |
| Allergan, INC. | $27.87 | 2019 | |
| Ani Pharmaceuticals, INC. | $26.65 | 2024 | Purified Cortrophin Gel |
| Carl Zeiss Meditec, INC. | $25.50 | 2019 | |
| Harrow Eye, LLC | $21.01 | 2024 | Vevye |
| Astellas Pharma US INC | $20.90 | 2025 | Izervay |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Wolf listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.